EU H2020 Project "OUTLIVE (OUTLIVE: a disruptive non-invasive ultrasound therapy to treat all patients..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/217160/index.html
-1	/open-h2020/projects/218494/index.html
-2	/open-h2020/projects/215785/index.html
-3	/open-h2020/projects/197942/index.html
-4	/open-h2020/per-topic/btob/list/index.html
-5	/open-h2020/projects/211957/index.html
-6	/open-h2020/projects/198764/index.html
-7	/open-h2020/projects/220685/index.html
-8	/open-h2020/per-topic/automate/list/index.html

OUTLIVE project word cloud

Explore the words cloud of the OUTLIVE project. It provides you a very rough idea of what is the project "OUTLIVE" about.

hospital medical consists valve establishments opening outlive adopters ultrasound untreated unlike imaging cumulative guided thanks perfusion business treating immense winner clinical cardiawave langevin risks ultrasounds created heart replacing 2030 risk valvosoft medtech poor device context safety unmet delivers complications gateway commercialisation sudden scalable game ready calcifies million plan threatening institut function dramatically refine revenues solution date sick cardiologists invasive world demonstrated contests blood combined care hegp expertise stenosis market exceeding narrowing health time prize repair ce therapy entrepreneur patients 25 caused solutions benefit physicians gold 1bn body age mark investor changer stiffens jobs disease leader treatment image aortic innovative death intensity trust causes strategy french standard efficacy relation accelerate revolutionary life

Project "OUTLIVE" data sheet

The following table provides information about the project.

Coordinator	CARDIAWAVE Organization address address: 12 RUE ALBERT ROUSSEL city: PARIS postcode: 75017 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	3˙563˙750 €
EC max contribution	2˙494˙625 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2021-06-30

#	participants	country	role	EC contrib. [€]
1	CARDIAWAVE	FR (PARIS)	coordinator	2˙494˙625.00

CARDIAWAVE

FR (PARIS)

coordinator

2˙494˙625.00

Project objective

Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.

Publications

List of publications.
year	authors and title	journal	last update
2019	D. Suarez Escudero, M. Tanter, M. Pernot FROM 2D TO 3D REAL-TIME PASSIVE CAVITATION IMAGING OF PULSED CAVITATION ULTRASOUND THERAPY published pages: , ISSN: , DOI:		2020-01-29
2019	M. Pernot, M. C. RÃ©mond, R. Penot, D. LadarrÃ©, Philippe Mateo, N. Ialy-Radio, D. Suarez, Guillaume Goudot, Wojciech Kwiecinski, Michael Vion, F. Betting, AurÃ©lien Corbel, Ana Fouquier, Sergio Cammarata, Eric NoÃ«l, Zahir Larabi, M. Tanter, E. Messas A new therapeutic device for transthoracic treatment of calcified aortic stenosis published pages: , ISSN: , DOI:		2020-01-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTLIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OUTLIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)